Cited by 1,575Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Open access

Phan, Giao Q., Yang, James C., Sherry, Richard M., Hwu, Patrick, Topalian, Suzanne L., Schwartzentruber, Douglas J., Restifo, Nicholas P., Haworth, Leah R., Seipp, Claudia A., Freezer, Linda J., Morton, Kathleen E., Mavroukakis, Sharon A., Duray, Paul H., Steinberg, Seth M., Allison, James P., Davis, Thomas A., Rosenberg, Steven A.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1533209100PMC PMC166236

Open this paper in CoChat — free account

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%), including dermatitis, enterocolitis, hepatitis, and hypophysitis, and mediated objective cancer regression in three patients (21%; two complete and one partial responses). This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy.

Integrity signals

Registry

Crossref · 10.1073/pnas.1533209100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786
Self-citation
A Theory of Self-Nonself Discrimination
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307

Show all 38 references

Research works printed but not linked: 4

Alegre, M. L., Frauwirth, K. A. & Thompson, C. B. (2002) Nat. Rev. Immunol. 1, 220-228.
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B. & Allison, J. P. (2000) Cancer Res. 60, 2444-2448.10811122
Pass, H. A., Schwarz, S. L., Wunderlich, J. R. & Rosenberg, S. A. (1998) Cancer J. Sci. Am. 4, 316-323.9815296
Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., Filomeni, G., Di Trapani, G., Clarke, F., Sitia, R. & Rubartelli, A. (2002) Proc. Natl. Acad. Sci. USA 99, 1471-1476.

Sorted by citations

Items 601–700 of 1,000

Immunotherapy in human colorectal cancer: Challenges and prospective
Sun, X., Suo, J., & Yan, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6362 · Cited by 50
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Dendritic cells: tools and targets for antitumor vaccination
den Brok, M. H., Nierkens, S., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.699 · Cited by 52
Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
Peggs, K. S., & Allison, J. P. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05627.x · Cited by 51
Self-citation
Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer?
Alhamarneh, O., Amarnath, S., Stafford, N. D., & Greenman, J. (2008) · Head & Neck · doi:10.1002/hed.20739 · Cited by 49
Autoantigens act as tissue-specific chemoattractants
Oppenheim, J. J., Dong, H., Plötz, P. H., Caspi, R. R., Dykstra, M. L., Pierce, S. K., Martinꝉ, R., Carlos, C. A., Finn, O. J., Koul, O., et al. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1004623 · Cited by 49
CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer
Karabon, L., Pawlak, E., Tomkiewicz, A., Jedynak, A., Passowicz−Muszyńska, E., Zajda, K., Jonkisz, A., Jankowska, R., Krzakowski, M. J., & Frydecka, I. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.05.010 · Cited by 48
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 52
High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women
Papasavvas, E., Surrey, L. F., Glencross, D. K., Azzoni, L., Joseph, J., Omar, T., Feldman, M. D., Williamson, A., Siminya, M., Swarts, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1128612 · Cited by 49
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
Bastacky, M. L., Wang, H., Fortman, D. D., Rahman, Z., Mascara, G. P., Brenner, T., Najjar, Y. G., Luke, J. J., Kirkwood, J. M., Zarour, H. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749064 · Cited by 49
Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor
Eini, H., Frishman, V., Yulzari, R., Kachko, L., Lewis, E. C., Chaimovitz, C., & Douvdevani, A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.092 · Cited by 47
Programmed death-1 as a factor in immune exhaustion and activation in HIV infection
Kaufmann, D., & Walker, B. D. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282f9ae8b · Cited by 47
Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer
Berzofsky, J. A., Terabe, M., & Wood, L. V. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.002 · Cited by 48
Clinical and Immunologic Basis of Interferon Therapy in Melanoma
Tarhini, A. A., & Kirkwood, J. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05073.x · Cited by 47
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017) · Current Drug Targets · doi:10.2174/1389450116666150518095346 · Cited by 47
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment
Chen, Y. (2016) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2016.08.005 · Cited by 47
Masterful Antibodies: Checkpoint Blockade
Lönberg, N., & Korman, A. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0057 · Cited by 47
The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma
Cranmer, L. D., & Hersh, E. M. (2007) · Cancer Investigation · doi:10.1080/07357900701522315 · Cited by 47
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
Verschraegen, C. F. (2012) · Cancer Management and Research · doi:10.2147/cmar.s15551 · Cited by 46
The New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 46
Paradigm Shifts in Cancer Vaccine Therapy
Schlom, J., Gulley, J. L., & Arlen, P. M. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-226 · Cited by 46
Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity
Lybaert, L., Vermaelen, K. Y., Geest, B. G. D., & Nuhn, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.009 · Cited by 46
Advances in Cutaneous Squamous Cell Carcinoma Management
Burns, C., Kubicki, S. L., Nguyen, Q. D., Aboul‐Fettouh, N., Wilmas, K. M., Chen, O. M., Doan, H. Q., Silapunt, S., & Migden, M. R. (2022) · Cancers · doi:10.3390/cancers14153653 · Cited by 49
Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity
Jovasevic, V. M., Gorelik, L., Bluestone, J. A., & MOKYR, M. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1449 · Cited by 46
CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation
Lingel, H., Wissing, J. B., Arra, A., Schanze, D., Lienenklaus, S., Klawonn, F., Pierau, M., Zenker, M., Jänsch, L., & Brunner-Weinzierl, M. C. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.102 · Cited by 46
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
Lee, C., Kakinuma, T., Wang, J., Zhang, H., Palmer, D. C., Restifo, N. P., & Hwang, S. T. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0310 · Cited by 46
Self-citation
Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy
Bauzon, M., & Hermiston, T. W. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00074 · Cited by 47
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 45
Towards progress on DNA vaccines for cancer
Lowe, D. B., Shearer, M. H., Jumper, C., & Kennedy, R. C. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7165-0 · Cited by 46
CTLA-4 Blockade: Unveiling Immune Regulation
Dranoff, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.923 · Cited by 46
Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001
Vetsika, E., Konsolakis, G., Aggouraki, D., Kotsakis, A. P., Papadimitraki, E., Christou, S., Menez-Jamet, J., Kosmatopoulos, K., Georgoulias, V., & Mavroudis, D. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1093-4 · Cited by 46
Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas
Sanchez-Perez, L. A., Kottke, T. J., Daniels, G. A., Díaz, R. M., Thompson, J., Pulido, J. S., Melcher, A. A., & Vile, R. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.4168 · Cited by 44
Emerging immunotherapies for glioblastoma
Desai, R. R., Suryadevara, C. M., Batich, K. A., Farber, S. H., Sanchez-Perez, L. A., & Sampson, J. H. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186643 · Cited by 46
Cancer vaccine strategies: translation from mice to human clinical trials
Berzofsky, J. A., Terabe, M., Trepel, J. B., Pastan, I. H., Stroncek, D. F., Morris, J. C., & Wood, L. V. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2084-x · Cited by 44
The genomic basis of tumor regression in Tasmanian devils (Sarcophilus harrisii)
Margres, M. J., Ruiz‐Aravena, M., Hamede, R., Jones, M. E., Lawrance, M. F., Hendricks, S. A., Patton, A. H., Davis, B. W., Ostrander, E. A., McCallum, H. I., et al. (2018) · Genome Biology and Evolution · doi:10.1093/gbe/evy229 · Cited by 44
The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases
Wojciechowicz, K., Spodzieja, M., Lisowska, K. A., & Wardowska, A. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104532 · Cited by 45
Tumor Regression following DNA Vaccination and Regulatory T Cell Depletion in neu Transgenic Mice Leads to an Increased Risk for Autoimmunity
Jacob, J. B., Kong, Y.-C. M., Nalbantoglu, I., Snower, D. P., & Wei, W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804074 · Cited by 44
Significance of B7-H1 Overexpression in Kidney Cancer
Thompson, R. H., & Kwon, E. D. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.038 · Cited by 44
Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines
D, S. M. M., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 44
Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade*
Allen, S. D., Rawale, S. V., Whitacre, C. C., & Kaumaya, P. T. P. (2005) · Journal of Peptide Research · doi:10.1111/j.1399-3011.2005.00256.x · Cited by 44
The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy
Damasio, M. P. S., Nascimento, C. S., de Andrade, L. M., de Oliveira, V. L., & Calzavara-Silva, C. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021609 · Cited by 46
Cystine‐knot peptides targeting cancer‐relevant human cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4)
Maaß, F., Wüstehube‐Lausch, J., Dickgießer, S., Valldorf, B., Reinwarth, M., Schmoldt, H., Daneschdar, M., Avrutina, O., Şahin, U., & Kolmar, H. (2015) · Journal of Peptide Science · doi:10.1002/psc.2782 · Cited by 43
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
Tykodi, S. S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s48443 · Cited by 43
Costimulation blockade: towards clinical application
Timothy, A. W. (2007) · Frontiers in bioscience · doi:10.2741/2829 · Cited by 43
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
Thompson, R. H., Allison, J. P., & Kwon, E. D. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.08.011 · Cited by 43
Self-citation
Profile of ipilimumab and its role in the treatment of metastatic melanoma
Woodman, S. E., & Patel (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s10945 · Cited by 42
Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance
Berrien-Elliott, M. M., Jackson, S. R., Meyer, J. M., Rouskey, C. J., Nguyen, T.-L. M., Yagita∥, H., Greenberg, P. D., DiPaolo, R. J., & Teague, R. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2179 · Cited by 42
Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy
Waldmann, T. A., & Morris, J. C. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90003-0 · Cited by 42
CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation
Zorn, E. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.008 · Cited by 42
Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis
Lo, J. W., Cozzetto, D., Alexander, J. L., Danckert, N. P., Madgwick, M., Knox, N., Sieh, J. Y. X., Olbei, M. L., Liu, Z., Ibraheim, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41798-2 · Cited by 43
Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports
Marlier, J., Cocquyt, V., Brochez, L., Belle, S. V., & Krüse, V. (2014) · Endocrine · doi:10.1007/s12020-014-0199-9 · Cited by 41
Prostate cancer vaccines
Geary, S. M., & Salem, A. K. (2013) · OncoImmunology · doi:10.4161/onci.24523 · Cited by 41
From Japan With Love: Another Tessera in the Hypophysitis Mosaic
Caturegli, P., & Iwama, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1912 · Cited by 41
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer
Ghochikyan, A., Av, P., Bagaev, A., Davtyan, A., Hovakimyan, A., Ильдарович, Т. А., Davtyan, H., Shcheblyakov, D. V., Logunov, D. Y., Chulkina, M., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0322-y · Cited by 41
Ipilimumab: From Preclinical Development to Future Clinical Perspectives in Melanoma
Letendre, P., Monga, V., Milhem, M. M., & Zakharia, Y. (2016) · Future Oncology · doi:10.2217/fon-2016-0385 · Cited by 43
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 41
Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation
Liang, Q., Zhou, L., Li, Y., Liu, J., & Liu, Y. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1927056 · Cited by 43
Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
Yi, H., Li, Y., Tan, Y., Fu, S., Tang, F., & Deng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648139 · Cited by 43
Increased CTLA-4 and FOXP3 Transcripts in Peripheral Blood Mononuclear Cells of Patients with Breast Cancer
Jaberipour, M., Habibagahi, M., Hosseini, A., Habibabad, S. R., Talei, A., & Ghaderi, A. A. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9256-8 · Cited by 41
Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40
SA-4-1BBL and Monophosphoryl Lipid A Constitute an Efficacious Combination Adjuvant for Cancer Vaccines
Srivastava, A. K., Dinc, G., Sharma, R. K., Yolcu, E. S., Zhao, H., & Shirwan, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1768-a · Cited by 40
Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer
Ramanathan, S., Gagnon, J., & Ilangumaran, S. (2008) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-008-0033-2 · Cited by 41
Addressing the unmet need in lung cancer: The potential of immuno-oncology
Scagliotti, G. V., Bironzo, P., & Vansteenkiste, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.001 · Cited by 41
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
Vikman, S., Sommaggio, R., Torre, M. D. L., Öberg, K., Essand, M., Giandomenico, V., Loskog, A., & Tötterman, T. H. (2008) · Acta Oncologica · doi:10.1080/02841860802438495 · Cited by 40
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
Afzal, M. Z., & Shirai, K. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000459 · Cited by 40
Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells
Reusch, U., Gall, F. L., Hensel, M., Moldenhauer, G., Ho, A. D., Little, M., & Kipriyanov, S. M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20417 · Cited by 41
Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma
Kämmerer, P. W., Toyoshima, T., Schöder, F., Kämmerer, P., Kuhr, K., Brieger, J., & Al‐Nawas, B. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.03.025 · Cited by 40
Human Suppressor of Cytokine Signaling 1 Controls Immunostimulatory Activity of Monocyte-Derived Dendritic Cells
Hong, B., Ren, W., Song, X., Evel-Kabler, K., Chen, S., & Huang, X. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1507 · Cited by 40
Autoimmune Toxicities Associated with the Administration of Antitumor Vaccines and Low-Dose Interleukin-2
Chianese‐Bullock, K. A., Woodson, E. M. H., Tao, H., Boerner, S. A., Smolkin, M. E., Grosh, W. W., Neese, P. Y., Merrill, P., Petroni, G. R., & Slingluff, C. L. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000171314.00924.2b · Cited by 40
Vaccines and Immunotherapeutics for the Treatment of Malignant Disease
Aldrich, J. F., Lowe, D. B., Shearer, M. H., Winn, R. E., Jumper, C., & Kennedy, R. C. (2010) · Journal of Immunology Research · doi:10.1155/2010/697158 · Cited by 41
Autoimmune Hypophysitis
Dalmazi, G. D., Caturegli, P., & Chalan, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00043-9 · Cited by 40
Improving Outcomes in Advanced Malignant Melanoma
Danson, S. J., & Lorigan, P. C. (2005) · Drugs · doi:10.2165/00003495-200565060-00002 · Cited by 40
Cytotoxic T-Lymphocyte Antigen-4 +49G/A Polymorphism Is Associated with Increased Risk of Osteosarcoma
Wang, W., Wang, J., Song, H., Liu, J., Song, B., & Cao, X. (2011) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2010.0264 · Cited by 39
A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay
Chaudhary, R., Quagliata, L., Jermann, P. M., Alborelli, I., Cyanam, D., Mittal, V., Tom, W., Au-Young, J. K., Sadis, S. E., & Hyland, F. C. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.01 · Cited by 42
Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy
Deng, C., Jia, M., Wei, G., Tan, T., Fu, Y. S., Gao, H., Sun, X., Zhang, Q., Gong, T., & Zhang, Z. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00932 · Cited by 39
Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review
Tao, W., Sun, Q., Xu, B., & Wang, R. (2025) · Life · doi:10.3390/life15020283 · Cited by 39
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
Yamane, B. H., Hank, J. A., Albertini, M. R., & Sondel, P. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048911 · Cited by 38
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers
Wang, G., Tai, R., Wu, Y., Yang, S., Wang, J., Yu, X., Lei, L., Shan, Z., & Li, N. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.02.002 · Cited by 38
Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up
Dadu, R., Rodgers, T. E., Trinh, V. A., Kemp, E. H., Cubb, T. D., Patel, S. P., Simon, J. M., Burton, E. M., & Tawbi, H. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000687 · Cited by 38
Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
Zulfiqar, B., Farooq, A. V., Kanwal, S., & Asghar, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1035171 · Cited by 42
Anticalins as an alternative to antibody technology
Schlehuber, S., & Skerra, A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.11.1453 · Cited by 38
Prostate Cancer Immunology: Biology, Therapeutics, and Challenges
Webster, W. S., Small, E. J., Rini, B. I., & Kwon, E. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4595 · Cited by 38
Nanovaccine Displaying Immunodominant T Cell Epitopes of Fibroblast Activation Protein Is Effective Against Desmoplastic Tumors
Shin, H., Kim, Y., & Jon, S. (2023) · ACS Nano · doi:10.1021/acsnano.3c00764 · Cited by 38
Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials
Sun, Z., Zhu, Y., Xia, J., Sawakami, T., Kokudo, N., & Zhang, N. (2015) · BioScience Trends · doi:10.5582/bst.2015.01128 · Cited by 37
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.012 · Cited by 37
The recent progress and therapy in endometriosis-associated ovarian cancer
Su, K., Wang, P., Yu, M.-H., Chang, C.-M., & Chang, C. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000262 · Cited by 38
Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences
Cohen, B. E., Manga, P., Lin, K., & Elbuluk, N. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00524-0 · Cited by 37
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee
Gastman, B., Agarwal, P. K., Berger, A., Boland, G. M., Broderick, S., Butterfield, L. H., Byrd, D. R., Fecci, P. E., Ferris, R. L., Fong, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001583 · Cited by 39
Self-citation
Rodent models of brain metastasis in melanoma
Cranmer, L. D., Trevor, K. T., Bandlamuri, S., & Hersh, E. M. (2005) · Melanoma Research · doi:10.1097/00008390-200510000-00002 · Cited by 37
Challenges for cancer vaccine development
Tabi, Z., & Man, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.004 · Cited by 37
From ‘Hellstrom Paradox–to anti-adenosinergic cancer immunotherapy
Lukashev, D. E., Sitkovsky, M. V., & Ohta, A. (2007) · Purinergic Signalling · doi:10.1007/s11302-006-9044-9 · Cited by 37
Advances in immune-based therapies of renal cell carcinoma
Lam, J. S., Belldegrun, A. S., & Figlin, R. A. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.6.1081 · Cited by 37
Overcoming immunological tolerance to melanoma: targeting CTLA-4
HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36
CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
Műzes, G., & Sípos, F. (2023) · Cells · doi:10.3390/cells12111534 · Cited by 39
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 36
Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 37
T cell coinhibition and immunotherapy in human breast cancer.
Janakiram, M., Abadi, Y. M., Sparano, J. A., & Zang, X. (2012) · PubMed · Cited by 36
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Agarwala, S. S., & Ribas, A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dcd260 · Cited by 36
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
Khouri, I. F., Curbelo, I. F., Turturro, F., Jabbour, E. J., Milton, D. R., Bassett, R. L., Vence, L. M., Allison, J. P., Gulbis, A. M., & Sharma, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2777 · Cited by 36
Self-citation
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.
Sun, J., Schiffman, J. S., Raghunath, A., Tang, D. N., Chen, H., & Sharma, P. (2008) · PubMed Central · Cited by 36

Authors: Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
Surgery Branch, Laboratory of Pathology, and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720; and Medarex, Inc., Princeton, NJ 08540
ORCID: Phan, Giao Q.
Yang, James C.
Sherry, Richard M.
Hwu, Patrick
Topalian, Suzanne L.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Steinberg, Seth M.
Allison, James P.
Davis, Thomas A.
Rosenberg, Steven A.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-06-25
Volume: 100
Issue: 14
Pages: 8372-8377
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1533209100
PMC: PMC166236
OpenAlex: W2134638467
Cited by: 1,575
References: 38
Citations by year: 2026: 10 · 2025: 11 · 2024: 26 · 2023: 41 · 2022: 48 · 2021: 52 · 2020: 58 · 2019: 56 · 2018: 68 · 2017: 82 · 2016: 58 · 2015: 72 · 2014: 70 · 2013: 78 · 2012: 72
FWCI: 46.70
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: CTLA-4 blockade, metastatic melanoma, autoimmunity, tumor regression, anti-CTLA-4 antibody, HLA-A*0201, cancer immunotherapy, self-tolerance, regulatory T cells, T cell activation, enterocolitis, hypophysitis, hepatitis, skin inflammation
MeSH terms: Adult, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colitis, Dermatitis, Female, Humans, Immune Tolerance, Immunotherapy, Injections, Intravenous, Injections, Subcutaneous, Lymphocyte Activation, Male, Melanoma, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasm Proteins, Peptide Fragments, Peptides, T-Lymphocytes, Cytotoxic, Vaccination, Vitiligo, Antigens, CD, HLA-A2 Antigen, T-Lymphocyte Subsets, Salvage Therapy, Hepatitis, Autoimmune, gp100 Melanoma Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks